RT Journal Article
SR Electronic
T1 Risks and Benefits of Antibiotics vs. COVID-19 Morbidity and Mortality
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.15.20213603
DO 10.1101/2020.10.15.20213603
A1 Tanioka, Hisaya
A1 Tanioka, Sayaka
YR 2020
UL http://medrxiv.org/content/early/2020/10/20/2020.10.15.20213603.abstract
AB Objectives The purpose is to analyze the potential association of each antibiotic consumption rate and use ratio with COVID-19 morbidity and mortality, and to investigate the efficacy and safe use of antibiotics against COVID-19.Design Retrospective statistical analysis study of antibiotic use compared with COVID-19 morbidity and mortality.Methods Each antibiotic defined daily dose (DDD) per 1000 inhabitants per day as each antibiotic consumption rate was available in the official reports and each antibacterial use ratio data was calculated from them. Coronavirus Disease data were obtained from the WHO Coronavirus Disease Dashboard. The relationships between the sum of DDD, each antibacterial DDD, each antibiotic use ratio, and COVID-19 morbidity and mortality were examined. The statistical correlation was calculated by univariate linear regression analysis and expressed by Pearson’s correlation coefficient.Results The sum of DDD had no statistical correlation with mortality and morbidity. Cephalosporins were a negative correlation with them. Penicillins had a weak positive correlation with them. Macrolides, quinolones, and sulfonates showed a slightly negative correlation tendency with mortality.Conclusions Cephalosporins may affect less COVID-19 morbidity and mortality. Penicillins suggest to accelerate them. The combination of cephalosporins with macrolides or quinolones may be a helpful treatment. The difference in antibiotic use between Japan and EU/EEA countries will suggest an explanation for the reduction in morbidity and mortality caused by COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo source of funding was used.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This retrospective study was approved by an institutional Research Ethics Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analyzed during this study are included in this article. https://www.ecdc.europa.eu/sites/default/files/documents/Antimicrobial-consumption-EU-EEA.pdf http://amrcrc.ncgm.go.jp/surveillance/020/sales_2020.pdf DDDDefined Daily DoseWHOWorld Health OrganizationCOVID-19Coronavirus Disease 2019HIVHuman Immunodeficiency VirusEBVEpstein–Barr virusCHIKVChikungunya virusSARS-CoV-2Severe Acute Respiratory Syndrome Coronavirus-2MERSMiddle East respiratory syndromeJ01A: TetTetracyclinesJ01C: PenPenicillinsJ01D: CephCephalosporins and other beta-lactamsJ01E: SulSulfonates and trimethoprimJ01F: MacMacrolides, lincosamides, and streptograminsJ01M: QuiQuinolones